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Background
Patients with atrial fibrillation (AF) who are at substantial risk of stroke and systemic thromboembolism require appropriate anticoagulation [1] . The CHA 2 DS 2 -VASc score and biomarker-based approaches were developed to aid in the assessment of stroke risk in patients with AF [2] . According to current European Society of Cardiology guidelines and international expert consensus, patients with paroxysmal AF and failure of pharmacologic therapy to improve symptoms in class IA are recommended to undergo catheter ablation [3, 4] . It was previously shown that cryoballoon ablation was noninferior to radiofrequency ablation with regard to efficacy and overall safety in this clinical indication [5] .
Case presentation
A 67-year-old hypertensive woman with a 5-year history of symptomatic (European Heart Rhythm Association [EHRA] symptom scale of III), drug-refractory paroxysmal AF, was admitted for pulmonary vein isolation (PVI). She had a CHA 2 DS 2 -VASc score of 2 and was anticoagulated with dabigatran 150 mg twice daily. The patient received her last dose of dabigatran the evening before
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Discussion and review of literature
Consideration of indications and contraindications for anticoagulation is crucial in patients with AF, and non-vitamin K antagonist oral anticoagulants play an increasing role in the treatment of patients with AF (Table) [3, 6, 7] . The decision on whether to interrupt oral anticoagulant treatment before cardiovascular implantable electronic device implantation and catheter ablation procedures is often unclear. These are generally considered as interventions with low bleeding risk, unless a complex anatomical setting is present or complex procedures are performed, respectively. However, complex left-sided ablations, including PVI, are regarded as interventions with a high bleeding and increased thromboembolic risk [7] . The current EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants (NOAC) recommends catheter ablation in patients who have been therapeutically anticoagulated with NOAC, generally without interruption or with a short cessation period of such treatment, depending on several factors, including CHA 2 DS 2 -VASc score, creatinine clearance, operator experience, and routine use of heparin before the first transseptal puncture [7] . Performance of catheter ablation during the use of dabigatran was tested in the Randomized Evaluation of Dabigatran Etexilate Compared to Warfarin in Pulmonary Vein Ablation: Assessment of an Uninterrupted Periprocedural Anticoagulation Strategy (RE-CIRCUIT) trial [8] . In this trial, patients received dabigatran at the usual time in the morning on the day of ablation and was associated with fewer bleeding complications than uninterrupted Mechanical heart valves or moderate-to-severe mitral stenosis; St. John's wort use; creatinine clearance <15 ml/min or dialysis; Child-Pugh category C.
Dronedarone use; creatinine clearance <30 ml/min (in the US, but not in Europe, dabigatran 75 mg twice a day has been approved for patients with a creatinine clearance 15-29 ml/min); ulceration of the digestive tract.
Dronedarone use in patients receiving rivaroxaban should be avoided. Rivaroxaban should not be used in patients with Child-Pugh category B.
Dose in atrial fibrillation 150 mg twice daily or 110 mg twice daily 20 mg once daily or 15 mg once daily 5 mg twice daily or 2.5 mg twice daily Selected indications for reduced dose Age ≥80 years or combining with verapamil. In younger patients ≥75 years, those with creatinine clearance ≤50 ml/min, gastro-oesophageal reflux disease, gastritis, esophagitis or at increased risk of bleeding consider individually.
Creatinine clearance <50 ml/min
Creatinine clearance <30 ml/min or at least two of: age ≥80 years and/or serum creatinine ≥1.5 mg/dl (133 µmol/l) and/or body weight ≤60 kg.
Safety concerns
Assess kidney function at least yearly (together with haemoglobin and liver function), in patients ≥75 years or frail at least every 6 months, if creatinine clearance ≤60 ml/min recheck interval = creatinine clearance / 10
Specific reversal agent Available (idarucizumab) Not yet approved and not yet available (andexanet alpha)
warfarin [8] . On the other hand, in cases of bleeding, measurement of the anticoagulant effect of the oral direct inhibitor of thrombin, may be required [9] . However, measurement of dabigatran plasma concentration is not widely available in all hospitals. Therefore, APTT may be useful in the assessment of the relative degree of anticoagulation with dabigatran. In patients receiving 150mg of dabigatran twice daily the median trough APTT is ~1.5 times higher than the level observed in controls, while a ratio of >2.5 may indicate supratherapeutic levels [9] . Moreover, a reversal agent for dabigatran (idarucizumab) is currently available, while a reversal agent for factor Xa inhibitors will likely be available in daily clinical practice in the near future [10, 11] . Idarucizumab was successfully tested in patients with serious bleeding and in those who require urgent procedures [10] . In the Reversal Effects of Idarucizumab on Active Dabigatran (RE-VERSE AD) study, idarucizumab was given in two separate bolus infusions, no more than 15 minutes apart (total of 5 g of idarucizumab), to patients in whom the median time since last intake of dabigatran was 15.4 hours (in 36% of patients, the last intake was <12 hours, while in 6% of patients this time was ≥48 hours) [10] .
There are published reports which show the importance of idarucizumab in specific urgent medical situations [12] [13] [14] . However, this case report and review of the literature highlight the potential clinical utility of idarucizumab in cardiology during catheter ablation. Pericardial effusion during pulmonary vein isolation occurs in < 1% of cases, however, if present, could lead to cardiac tamponade and death [15] . Therefore, the choice of an optimal anticoagulant agent is crucial.
Conclusion
There is no necessity to interrupt anticoagulation treatment with dabigatran before AF ablation if idarucizumab is available. Idarucizumab increases the safety of PVI in patients treated with dabigatran.
